Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,895.60
(
-0.50%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
101.04
(
2.78%
)
Bitcoin
74,396.60
(
-0.60%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 87691

Thursday, 12/17/2009 4:00:19 PM

Thursday, December 17, 2009 4:00:19 PM

Post# of 257250
PYMX MNTA:

I hadn't quite realized the growing dominance of Lovenox (seems to currently have about 80% of the LMWH market as best I can tell)…

It’s even more than that. According to SNY, Lovenox’s share of the US market for LMWH’s is about 95%; Fragmin and InnoHep have 1-2% each, and everything else is essentially round-off error.

Arixtra, which is not a LMWH, is also a non-factor in the market despite its being a fine drug.

In short, the heparin-based market boils down to two products: UFH and Lovenox.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now